lutetium has been researched along with Bone Cancer in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.26) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 18 (46.15) | 24.3611 |
| 2020's | 10 (25.64) | 2.80 |
| Authors | Studies |
|---|---|
| Flux, G; Liepe, K; Murray, I | 1 |
| Chen, Y; Su, D; Yang, H; Zhang, Y | 1 |
| Ahmadzadehfar, H; Brossart, P; Essler, M; Feldmann, G; Fimmers, R; Hauser, S; Holdenrieder, S; Linden, P; Yordanova, A | 1 |
| Deryabina, D; Mostafa, MYA; Zakaly, HMH; Zhukovsky, M | 1 |
| Martins, H; Moreira, AP; Silva, R; Soeiro, P | 1 |
| Ahmadzadehfar, H; Bundschuh, RA; Essler, M; Gaertner, FC; Khawar, A; Kreppel, B; Kürpig, S; Meisenheimer, M; Roesch, F | 1 |
| Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M | 1 |
| Buyukkaya, F; Ekenel, M; Has Simsek, D; Isik, EG; Kovan, B; Kuyumcu, S; Özkan, ZG; Sanli, Y; Turkmen, C | 1 |
| Bakar, HE; Begec, T; Cayırlı, YB; Celen, YZ; Elboga, U; Eryilmaz, K; Kilbas, B; Mercanoglu, G; Sahin, E | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Nava-Cabrera, M; Oros-Pantoja, R | 1 |
| Chakraborty, S; Chakravarty, R; Dash, A; Kamaleshwaran, K; Radhakrishnan, E; Rajeswari, A; Sarma, HD; Shinto, AS; Vimalnath, KV | 1 |
| Aryana, K; Divband, G; Salek, R; Zarehparvar Moghadam, S | 1 |
| Ballinger, JR | 1 |
| Ferretti, A; Gross, MD; Rubello, D; Viglianti, BL; Wale, DJ; Wong, KK | 1 |
| Gans, R; Lam, M; Stam, A; van Kalmthout, L | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Ferro-Flores, G; Jiménez-Mancilla, N; Nava-Cabrera, MA; Rojas-Calderón, E | 1 |
| Aghdam, RA; Hashemifard, H; Norouzi, G; Pirayesh, E | 1 |
| Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ | 1 |
| Korde, A; Kumar, C; Lohar, SP; Samuel, G; Vats, K | 1 |
| Guerra Liberal, FD; Tavares, AA; Tavares, JM | 1 |
| Banerjee, S; Das, T; Kamaleshwaran, KK; Sarma, HD; Shinto, A | 1 |
| Baum, RP; Meckel, M; Nauth, A; Puranik, AD; Rösch, F; Timpe, J; Zhernosekov, K | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
| Beerens, CE; de Jong, M; Doukas, M; Nonnekens, J; Suker, M; van Eijck, CH; van Gent, DC; van Kranenburg, M | 1 |
| Bal, C; Ballal, S; Tripathi, M; Yadav, MP | 1 |
| Ahmadzadehfar, H; Bögemann, M; Rahbar, K | 1 |
| Bode, A; Bögemann, M; Rahbar, K; Roll, W; Weckesser, M | 1 |
| Geramifar, P; Kamali Asl, A; Khazaee Moghadam, M; Zaidi, H | 1 |
| Berent, LM; Bommarito, D; Bryan, JN; Bryan, ME; Cutler, C; Engelbrecht, H; Henry, CJ; Ketring, A; Kim, DY; Lattimer, JC | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Venkatesh, M | 1 |
| Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Sarma, HD; Venkatesh, M | 1 |
| Gössner, W; Luz, A; Müller, WA; Schäffer, EH | 1 |
| Linzner, U; Luz, A; Müller, WA; Schäffer, EH | 1 |
| Linzner, U; Müller, WA; Scháffer, EH | 1 |
| Ando, A; Ando, I; Fujita, N; Kataiwa, A; Kazuma, K; Kinuya, S; Nakagawa, M; Tonami, N | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Pillai, MR; Ramamoorthy, N; Samuel, G; Sarma, HD; Unni, PR; Venkatesh, M | 1 |
| Atkinson, MJ; Erfle, V; Gössner, W; Linzner, U; Luz, A; Müller, K; Müller, WA; Murray, AB; Schmidt, J; Strauss, PG | 1 |
| Luz, A; Müller, WA; Schäffer, EH | 1 |
4 review(s) available for lutetium and Bone Cancer
| Article | Year |
|---|---|
Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases.
Topics: Bone and Bones; Bone Neoplasms; Humans; Lutetium; Pain; Radiopharmaceuticals; Rhenium; Tissue Distribution; Zoledronic Acid | 2022 |
Theranostic radiopharmaceuticals: established agents in current use.
Topics: 3-Iodobenzylguanidine; Antigens, CD20; Bone Neoplasms; Dipeptides; Diphosphonates; Drug Approval; Forecasting; Heterocyclic Compounds, 1-Ring; Hodgkin Disease; Humans; Iodine Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Prostate-Specific Antigen; Radiopharmaceuticals; Somatostatin; Theranostic Nanomedicine; Thyroid Diseases | 2018 |
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium | 2019 |
Bone tumor induction after incorporation of short-lived radionuclides.
Topics: Animals; Bone Neoplasms; Lutetium; Mice; Neoplasms, Radiation-Induced; Radium; Thorium | 1991 |
1 trial(s) available for lutetium and Bone Cancer
| Article | Year |
|---|---|
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
34 other study(ies) available for lutetium and Bone Cancer
| Article | Year |
|---|---|
Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
The value of tumor markers in men with metastatic prostate cancer undergoing [
Topics: Aged; Biomarkers, Tumor; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kaplan-Meier Estimate; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2020 |
Comparative studies on the potential use of
Topics: Bone Neoplasms; Humans; Kinetics; Lutetium; Palliative Care; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage | 2020 |
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Humans; Liver Neoplasms; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Receptors, Peptide; Remission Induction | 2020 |
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinoma.
Topics: Bone Neoplasms; Carcinoma, Bronchogenic; Humans; Lutetium; Radioisotopes; Zoledronic Acid | 2020 |
Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04.
Topics: Adult; Bone Neoplasms; Endopeptidases; Humans; Lutetium; Male; Membrane Proteins; Middle Aged; Quinolines; Radiation Dosage; Radioisotopes; Radiometry; Radiotherapy Dosage; Safety; Single Photon Emission Computed Tomography Computed Tomography | 2021 |
An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical.
Topics: Aged; Automation; Bone Neoplasms; Female; Humans; Injections, Intravenous; Lutetium; Male; Molecular Structure; Organometallic Compounds; Pain; Pain Management; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals | 2021 |
Comparison between
Topics: Actinium; Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lutetium; Mice, Nude; Neoplasm Metastasis; Radioisotopes; Radiometry | 2021 |
A "mix-and-use" approach for formulation of human clinical doses of
Topics: Animals; Bone Neoplasms; Cancer Pain; Durapatite; Humans; Lutetium; Male; Organophosphorus Compounds; Pharmacy Service, Hospital; Radioisotopes; Rats; Tissue Distribution | 2017 |
177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
Topics: Aged; Biological Transport; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Treatment Outcome; Whole Body Imaging | 2018 |
Visual deficit possibly caused by lutetium-177 PSMA treatment.
Topics: Bone Neoplasms; Diagnosis, Differential; Humans; Lutetium; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Vision Disorders | 2018 |
Assessment of the radiation absorbed dose produced by
Topics: Actinium; Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Computer Simulation; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Models, Biological; Monte Carlo Method; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Tumor Microenvironment | 2019 |
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
Topics: Aged; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2019 |
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate | 2013 |
Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; CHO Cells; Combined Modality Therapy; Cricetulus; Drug Synergism; Humans; Lutetium; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Radioisotopes; Radiopharmaceuticals | 2014 |
Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
Topics: Algorithms; Beta Particles; Bone Neoplasms; Computer Simulation; DNA; DNA Damage; DNA Repair; Humans; Lutetium; Monte Carlo Method; Neoplasm Metastasis; Palliative Care; Radioisotopes; Radiopharmaceuticals; Radium; Rhenium; Samarium; Strontium Radioisotopes | 2014 |
Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Topics: Animals; Bone and Bones; Bone Neoplasms; Chemistry, Pharmaceutical; Freeze Drying; Humans; Hydrogen-Ion Concentration; Lutetium; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Quality of Life; Radiochemistry; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Reagent Kits, Diagnostic; Temperature; Tissue Distribution | 2014 |
Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Topics: Aged; Amides; Bone and Bones; Bone Neoplasms; Diphosphonates; Humans; Lutetium; Male; Pain; Radioisotopes; Radiopharmaceuticals; Reagent Kits, Diagnostic; Staining and Labeling | 2015 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Topics: Bone Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA, Neoplasm; Drug Synergism; Genomic Instability; Humans; Lutetium; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy; Receptors, Somatostatin | 2016 |
Reply to Rahbar K et al.
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiotherapy; Treatment Outcome | 2017 |
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiotherapy; Treatment Outcome | 2017 |
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Topics: Aged; Bone Neoplasms; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2017 |
Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
Topics: Algorithms; Bone Neoplasms; Computer Simulation; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Monte Carlo Method; Organ Specificity; Phosphorus Radioisotopes; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Planning, Computer-Assisted; Water; Yttrium Radioisotopes | 2016 |
Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
Topics: Animals; Blood Cell Count; Bone Marrow; Bone Neoplasms; Dogs; Female; Lutetium; Male; Organometallic Compounds; Organophosphorus Compounds; Radiation Dosage; Radioisotopes; Samarium | 2009 |
177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Topics: Animals; Bone Neoplasms; Heterocyclic Compounds, 1-Ring; Lutetium; Organophosphonates; Organophosphorus Compounds; Pain; Palliative Care; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution | 2002 |
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed | 2007 |
Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Topics: Animals; Bone Neoplasms; Drug Stability; Lutetium; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Rabbits; Radioisotopes; Rats; Rats, Wistar; Tissue Distribution | 2008 |
The role of time-factor and RBE for the induction of osteosarcomas by incorporated short-lived bone-seekers.
Topics: Animals; Bone Neoplasms; Lutetium; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Osteosarcoma; Radioisotopes; Radium; Relative Biological Effectiveness; Strontium Radioisotopes; Thorium; Time Factors | 1983 |
Incorporation experiments with combined application of different bone seekers.
Topics: Actinium; Animals; Body Burden; Bone and Bones; Bone Neoplasms; Cocarcinogenesis; Dose-Response Relationship, Radiation; Lutetium; Mice; Neoplasms, Radiation-Induced; Neptunium; Osteosarcoma; Plutonium; Radioisotopes | 1984 |
Studies on incorporated short-lived beta-emitters with regard to the induction of late effects.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Liver; Lutetium; Mice; Neoplasms, Radiation-Induced; Osteosarcoma; Radioisotopes; Samarium; Time Factors | 1980 |
177Lu-EDTMP: a potential therapeutic bone agent.
Topics: Animals; Beta Particles; Bone and Bones; Bone Neoplasms; Femur; Gamma Rays; Humans; Lutetium; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Radiopharmaceuticals; Rats; Rats, Wistar; Technetium Tc 99m Medronate; Time Factors; Tissue Distribution | 1998 |
177Lu labelled polyaminophosphonates as potential agents for bone pain palliation.
Topics: Animals; Bone Neoplasms; Isotope Labeling; Ligands; Lutetium; Magnetic Resonance Spectroscopy; Organophosphonates; Pain, Intractable; Palliative Care; Phosphoramides; Polyamines; Quality Control; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Spectrophotometry, Infrared; Tissue Distribution | 2002 |
The osteosarcomogenic efficiency of low 224radium-doses in mice compared to that of the short-lived beta-emitting rare earth 177lutetium.
Topics: Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Female; Lutetium; Mice; Neoplasms, Radiation-Induced; Radioisotopes; Radium; Sarcoma, Experimental; Thorium | 1985 |